Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Is Central Sensitization a Predictor of Short-Term Change in Chronic Nonspecific Low Back Pain?

Official title: The Prognostic Role of Central Sensitization in Short-Term Clinical Outcomes in Chronic Nonspecific Low Back Pain

Run by Mardin Artuklu University · NCT07826546 · Data updated 2026-11-12

This study tests whether higher baseline central nervous system sensitivity can predict short-term improvements in disability and pain for adults with chronic nonspecific low back pain.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment180 (estimated)
SponsorMardin Artuklu University
Academic / other
Locations1 site (Mardin)
StatusRecruiting
StartedJune 1, 2026
Main results expectedJune 1, 2027
Study endsJune 1, 2027
Registry record updatedSeptember 17, 2026
Trial IDNCT07826546 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with chronic nonspecific low back pain for at least 3 months are eligible, excluding those with certain neurological, inflammatory, malignant, or cognitive conditions or recent changes to antidepressant/gabapentinoid therapy.

Probably not a fit

Patients with high-risk exclusions or those who receive no effective change with routine care may not experience a detectable benefit from this observational approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study examines adults with chronic nonspecific low back pain to see if initial signs of central sensitization, measured by the Central Sensitization Inventory, are linked to 6-week clinical outcomes. Participants complete questionnaires on sensitivity, disability, pain, and mood at baseline, then reassess disability, pain, and overall change after six weeks while receiving routine care. A 30% reduction in disability is considered a meaningful improvement. No new treatments are assigned by the study; outcomes relate to standard clinical management. The study aims to clarify whether baseline sensitization helps predict short-term response to care.

Why it matters

Potential benefit: If successful, baseline central sensitization could help clinicians anticipate which patients may experience greater or lesser short-term benefit from routine care.

How similar studies have gone: Previous research has explored central sensitization as a prognostic factor in musculoskeletal pain, with mixed but informative findings for short-term outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 18 to 65 years
* Diagnosis of chronic nonspecific low back pain lasting for at least 3 months
* Willingness to participate in the study
* Ability to provide written informed consent

Exclusion Criteria:

* Progressive neurological deficit
* Inflammatory rheumatic disease
* Active malignancy
* History of serious spinal trauma or spinal surgery
* Cognitive impairment that may prevent completion of the assessments or follow-up
* Initiation, dose modification, or change of antidepressant or gabapentinoid treatment within the previous 3 months
* Pregnancy, postpartum period, or breastfeeding
* Inability to provide informed consent

Where it's running

  • Mardin Training and Research Hospital
    Mardin, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.